The Pharmacy Behind Your Prescription: Who's Actually Compounding Your GLP-1

Here's something most patients don't think about until something goes wrong: when you order compounded semaglutide from a telehealth platform, the platform isn't making the medication. They're writing a prescription and having a compounding pharmacy fill it.

The pharmacy is the one measuring the active ingredient, combining it with the sterile diluent, filling the vials, and shipping to you. Everything about the quality, potency, and safety of your medication depends on that pharmacy's practices — not your telehealth brand's marketing.

Most platforms don't prominently disclose which pharmacy is compounding your medication. That's worth understanding, because the differences between compounding pharmacies are meaningful.

503A vs. 503B: the regulatory distinction that matters

Compounding pharmacies in the United States operate under one of two regulatory frameworks, defined by the Drug Quality and Security Act of 2013:

503A pharmacies (traditional compounding)

503A pharmacies compound medications in response to specific patient prescriptions. Each prescription is, technically, a one-off preparation for a named patient. They're licensed by state boards of pharmacy, not directly regulated by the FDA. Most community compounding pharmacies and the pharmacies behind most telehealth compounded GLP-1 products are 503A.

• Regulation: State boards of pharmacy, with some FDA oversight via FDCA.
• Batch sizes: Patient-specific; smaller quantities.
• cGMP compliance: Not required (though some follow voluntarily).
• Sterility testing: Required by USP <797> standards but enforcement varies.
• Reporting to FDA: Limited.

503B outsourcing facilities (larger-scale compounding)

503B facilities register directly with the FDA and can compound in larger batches without patient-specific prescriptions. They're held to stricter standards — essentially closer to pharmaceutical manufacturing than traditional pharmacy compounding. They're the middle ground between 503A pharmacies and FDA-approved drug manufacturers.

• Regulation: FDA directly registers, inspects, and oversees.
• Batch sizes: Larger, non-patient-specific allowed.
• cGMP compliance: Required (current Good Manufacturing Practice).
• Sterility testing: Mandatory for all sterile products.
• Adverse event reporting: Required to FDA.

Why this matters for GLP-1 medications

Compounded semaglutide and tirzepatide are sterile injectable products. That means:

• Contamination risk exists at every step from API receipt to vial filling.
• Potency can vary if measurement isn't precise.
• Stability depends on proper storage and handling conditions.
• Endotoxin testing, sterility testing, and USP <797> compliance matter.

A well-run 503A pharmacy can produce reliable, safe compounded GLP-1 medications. A poorly-run one can produce unsafe products. The regulatory floor is lower for 503A than for 503B or for FDA-approved manufacturers, which means the variance is greater.

Which pharmacies are behind which telehealth brands?

Most telehealth companies consider their pharmacy partners proprietary information and don't publicly disclose them. That said, patterns are visible through state pharmacy board filings, shipping labels, and patient reports:

The disclosure landscape is improving. Platforms increasingly recognize that pharmacy transparency is becoming a competitive differentiator as patients get more sophisticated. Several platforms now list pharmacy partners publicly or disclose on request.

What makes a reputable compounding pharmacy

How to ask your telehealth provider about the pharmacy

You have every right to know who's making your medication. Questions worth asking during intake:

1. "Which compounding pharmacy fills my prescription?" If they won't tell you, that's meaningful.
2. "Is the pharmacy a 503A or 503B facility?" Both can be legitimate; the answer tells you what framework applies.
3. "Is the pharmacy LegitScript-accredited?" Third-party verification is meaningful.
4. "Where is the API (semaglutide or tirzepatide) sourced from?" Reputable answers cite established US or European manufacturers or specific FDA-registered facilities.
5. "Do you have sterility and potency testing documentation for compounded batches?" Yes or no should be a simple answer.

Providers that handle these questions transparently are generally the ones worth working with. Providers who treat them as adversarial or can't answer are a signal to look elsewhere.

The API sourcing question

The active pharmaceutical ingredient (API) — semaglutide or tirzepatide in powder form — is what the pharmacy mixes with sterile diluent to create your injection. API can come from:

• Established US or European pharmaceutical API manufacturers operating under FDA/EMA oversight. This is the gold standard.
• Chinese or Indian API suppliers registered with the FDA. Many are reputable; FDA inspection history matters.
• Unregistered or gray-market suppliers. Avoid. Quality is unreliable and may contain unknown impurities.

Reputable 503A and 503B pharmacies source from FDA-registered facilities. The ones cutting corners source from cheaper, unregulated suppliers. You typically can't tell which is which without asking.

Signs your compounded medication might have quality issues

• Inconsistent effects between batches. If one vial produces dramatically different appetite suppression than another at the same dose, potency variance is possible.
• Unusual physical appearance. Cloudy solutions, visible particulates, or color variations warrant immediate pharmacy contact.
• Injection-site reactions worse than typical. Localized reactions can indicate contamination or irritant impurities.
• Reduced efficacy over time. Some patients experience gradual weight loss plateau that may be medication-related rather than physiological.

None of these are definitive — all can have non-pharmacy explanations. But if you're experiencing multiple signs, contacting your provider to ask about the specific batch and pharmacy source is reasonable.

The weight-based dosing nuance

Compounded GLP-1s are often dosed based on volume (milliliters) from a single-concentration vial, while FDA-approved semaglutide pens deliver precise milligram doses. This can create confusion:

• Compounded semaglutide commonly arrives as a 5mg/mL or 2.5mg/mL concentration vial. You draw the appropriate volume.
• Dosing errors can happen if you misread the concentration or make a unit conversion mistake.
• Compound-to-compound variation means a "standard dose" from one pharmacy may be different from another.

Reputable pharmacies provide clear dosing instructions with each shipment. If your instructions aren't crystal clear, ask.

What to expect from quality compounded medication

The FDA-approved alternative

If compounding pharmacy uncertainty bothers you, FDA-approved Wegovy and Zepbound are now priced competitively:

• Wegovy on Novo Nordisk's 12-month subscription through Ro, Hims & Hers, WeightWatchers, Sesame, or LifeMD: $249/mo
• Zepbound vials through LillyDirect: $299–449/mo depending on dose
• Oral Wegovy (tablets 1.5mg and 4mg): $149/mo through August 2026

These are FDA-approved products manufactured by Novo Nordisk or Eli Lilly, respectively. Regulatory oversight is complete. For patients prioritizing FDA approval, this is the cleanest path.

Cross-reference: glp-1compoundpharmacy.com

For deep-dive coverage of specific compounding pharmacies, their accreditation histories, FDA inspection records, and patient-reported quality data, our sister site glp-1compoundpharmacy.com is dedicated entirely to this topic. If you want to research a specific pharmacy by name or understand compounding quality in more detail than fits here, that's the resource.

Bottom line

The pharmacy behind your compounded GLP-1 matters. 503A pharmacies operating responsibly under state oversight can produce safe, effective medications — but the regulatory floor is lower than for FDA-approved manufacturing, so variance matters.

If you're choosing a compounded provider, prioritize ones that disclose their pharmacy partnerships, work with LegitScript-accredited facilities, and can answer specific questions about sterility, potency, and API sourcing. The cheapest providers often cut corners in ways that don't show up on marketing pages but do show up in product quality.

If pharmacy uncertainty bothers you enough, FDA-approved Wegovy at $249/month on a 12-month subscription eliminates the compounding question entirely. That's a reasonable trade-off — a little more money for complete regulatory clarity.

Either path is defensible. Just make the choice with full understanding of what you're actually buying.